echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Traditional Chinese medicine formula granules will open up a market of 100 billion yuan in the future, and this industry may follow the "light"

    Traditional Chinese medicine formula granules will open up a market of 100 billion yuan in the future, and this industry may follow the "light"

    • Last Update: 2022-10-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Jilin Aodong issued an announcement on the evening of October 25 that Yanbian Pharmaceutical, a holding subsidiary of the company, recently obtained 6 "Chinese Medicine Formula Granules Listing Filing Certificates"
    .
    Up to now, Yanbian Pharmaceutical has obtained a total of 208 "Listing Certificates for Traditional Chinese Medicine Formula Granules"
    .

     
    Chinese medicine formula granules are granules made of single-flavor Chinese medicine pieces extracted, separated, concentrated, dried and granulated by water heating, and are prepared according to the clinical prescription of traditional Chinese medicine under the guidance of traditional Chinese medicine theory for patients to take and use
    .

     
    Formulated granules will open up a market of 100 billion
     
    It is understood that since November 2021, Chinese medicine formula granules have begun to switch to the new national standard, gradually upgrading to provincial standards and national standards, and this year has also been in the national standard switching period, but the implementation progress of traditional Chinese medicine formula granules in various places is different, resulting in different
    filing progress.

     
    As of September this year, the National Pharmacopoeia Commission has announced 200 national standard varieties of Chinese medicine formula granules, another 69 varieties are in the publicity period, and the progress of mutual recognition of provincial standards is gradually accelerating.


     
    A new research report released by Southwest Securities said that the pharmaceutical market in the third quarter of this year is mainly based on national standard and provincial standard formula granules, and national standard products are expected to gradually achieve volume
    in the third and fourth quarters of this year.
    From the price point of view, after the formula granules replace the national standard, the price increases by 80-100% on average, and from the quantitative point of view, the provinces accelerate the inclusion of formula granules in the medical insurance progress to ensure the accessibility of
    patients.
    The bank expects that the future formula granules will open up a market
    of 100 billion.

     
    Traditional Chinese medicine formula granules will open up a market of 100 billion yuan in the future, and this industry may follow the "light" (Image source: Pharma Network)
     
    Related equipment industry or follow the "light"
     
    Faced with the future development opportunities of the Chinese medicine formula granule industry, pharmaceutical companies have accelerated the progress of Chinese medicine formula granule projects and the filing of varieties, at the same time, the production capacity of some pharmaceutical companies can no longer meet the growing market demand, so the production capacity is also facing expansion
    .

     
    For example, Yiling Pharmaceutical said in an institutional research activity at the end of August that the company has accelerated the research and development and filing of new standard formula granules (national standard/provincial standard), and has completed the listing and filing of
    more than 300 new standard formula granule varieties.
    At the same time, we will actively increase the number of Chinese medicine formula granule and herbal medicine bases, expand the production capacity of Chinese medicine formula granules, expand the sales team, and seize market opportunities
    .
    In 2021, the revenue of formulated granules of Yiling Pharmaceutical will be 95 million yuan, a year-on-year increase of 280%, and it is expected to maintain rapid growth
    in the next few years.

     
    Liuzhou Group also said in September in institutional research activities that the company's traditional Chinese medicine formula granule project design reached 3,000 tons, of which the first phase of production capacity of about 1,500 tons has been completed and gradually put into production, the company is continuing to carry out product filing work, has completed the filing of about 130 varieties, this part of the varieties have been put on sale
    .
    The company strives to complete the filing of more than 180 varieties of national standard, about 150 varieties of provincial standard, a total of about 300~350 varieties, basically covering the commonly used traditional Chinese medicine formula granule products
    in hospitals.

     
    Under the background of major pharmaceutical companies accelerating product filing and putting into production, the industry expects that the related equipment industry in the industry chain of traditional Chinese medicine formula granules may follow suit
    .

     
    However, due to the stricter quality requirements of Chinese medicine formula granules, the requirements for equipment are relatively high
    .
    The relevant documents stipulate that formula granule manufacturers need to concoct Chinese medicine pieces for the production of Chinese medicine formula granules, and must have complete production capacity in the whole process of Chinese medicine preparation, extraction, separation, concentration, drying and granulation, which is an opportunity and challenge for the related equipment industry
    .

     
    In addition, the document stipulates the application of feature map quality control technology for formula granule manufacturers, which means that enterprises will also face cost pressure caused by the equipment required for feature mapping, and how to help enterprises reduce costs and increase efficiency is a topic
    that equipment companies need to continue to think about and explore.

     
    Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
    to anyone.

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.